Literature DB >> 23554468

Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response.

Catia T Perciani1, Giovana C Barazzone, Cibelly Goulart, Eneas Carvalho, Joaquin Cabrera-Crespo, Viviane M Gonçalves, Luciana C C Leite, Martha M Tanizaki.   

Abstract

Despite the substantial beneficial effects of incorporating the 7-valent pneumococcal conjugate vaccine (PCV7) into immunization programs, serotype replacement has been observed after its widespread use. As there are many serotypes currently documented, the use of a conjugate vaccine relying on protective pneumococcal proteins as active carriers is a promising alternative to expand PCV coverage. In this study, capsular polysaccharide serotype 6B (PS6B) and recombinant pneumococcal surface protein A (rPspA), a well-known protective antigen from Streptococcus pneumoniae, were covalently attached by two conjugation methods. The conjugation methodology developed by our laboratory, employing 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM) as an activating agent through carboxamide formation, was compared with reductive amination, a classical methodology. DMT-MM-mediated conjugation was shown to be more efficient in coupling PS6B to rPspA clade 1 (rPspA1): 55.0% of PS6B was in the conjugate fraction, whereas 24% was observed in the conjugate fraction with reductive amination. The influence of the conjugation process on the rPspA1 structure was assessed by circular dichroism. According to our results, both conjugation processes reduced the alpha-helical content of rPspA; reduction was more pronounced when the reaction between the polysaccharide capsule and rPspA1 was promoted between the carboxyl groups than the amine groups (46% and 13%, respectively). Regarding the immune response, both conjugates induced functional anti-rPspA1 and anti-PS6B antibodies. These results suggest that the secondary structure of PspA1, as well as its reactive groups (amine or carboxyl) involved in the linkage to PS6B, may not play an important role in eliciting a protective immune response to the antigens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23554468      PMCID: PMC3675967          DOI: 10.1128/CVI.00754-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  47 in total

1.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials.

Authors:  C Cornu; D Yzèbe; P Léophonte; J Gaillat; J P Boissel; M Cucherat
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

3.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

4.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

5.  Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae.

Authors:  S K Hollingshead; R Becker; D E Briles
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Lowry protein assay using an automatic microtiter plate spectrophotometer.

Authors:  H J Fryer; G E Davis; M Manthorpe; S Varon
Journal:  Anal Biochem       Date:  1986-03       Impact factor: 3.365

7.  Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells.

Authors:  Cibelly Goulart; Michelle Darrieux; Dunia Rodriguez; Fabiana C Pimenta; Maria Cristina C Brandileone; Ana Lucia S S de Andrade; Luciana C C Leite
Journal:  Vaccine       Date:  2011-01-04       Impact factor: 3.641

8.  Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.

Authors:  D E Briles; S K Hollingshead; J King; A Swift; P A Braun; M K Park; L M Ferguson; M H Nahm; G S Nabors
Journal:  J Infect Dis       Date:  2000-11-08       Impact factor: 5.226

9.  Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.

Authors:  P Anderson; M E Pichichero; R A Insel
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

10.  Characterization of the murine immune response to type 6 pneumococcal polysaccharide.

Authors:  R L Fairchild; H Braley-Mullen
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

View more
  7 in total

1.  Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.

Authors:  Míriam A da Silva; Thiago R Converso; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki; Giovana C Barazzone
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  Identification of glycosylated regions in pneumococcal PspA conjugated to serotype 6B capsular polysaccharide.

Authors:  Giovana Cappio Barazzone; Vittoria Pinto; Danilo Donnarumma; Martha Massako Tanizaki; Nathalie Norais; Francesco Berti
Journal:  Glycoconj J       Date:  2014-04       Impact factor: 2.916

3.  Chemical cross-linking/mass spectrometry targeting acidic residues in proteins and protein complexes.

Authors:  Alexander Leitner; Lukasz A Joachimiak; Pia Unverdorben; Thomas Walzthoeni; Judith Frydman; Friedrich Förster; Ruedi Aebersold
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-17       Impact factor: 11.205

4.  Subcutaneous Immunization with Fusion Protein DnaJ-ΔA146Ply without Additional Adjuvants Induces both Humoral and Cellular Immunity against Pneumococcal Infection Partially Depending on TLR4.

Authors:  Yufeng Su; Dagen Li; Yan Xing; Hong Wang; Jian Wang; Jun Yuan; Xiaofang Wang; Fang Cui; Yibing Yin; Xuemei Zhang
Journal:  Front Immunol       Date:  2017-06-12       Impact factor: 7.561

5.  Structural basis for fragmenting the exopolysaccharide of Acinetobacter baumannii by bacteriophage ΦAB6 tailspike protein.

Authors:  I-Ming Lee; I-Fan Tu; Feng-Ling Yang; Tzu-Ping Ko; Jiahn-Haur Liao; Nien-Tsung Lin; Chung-Yi Wu; Chien-Tai Ren; Andrew H-J Wang; Ching-Ming Chang; Kai-Fa Huang; Shih-Hsiung Wu
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

6.  ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification.

Authors:  Valdemir M Cardoso; Sheyla A H Paredes; Gilson Campani; Viviane M Gonçalves; Teresa C Zangirolami
Journal:  Appl Microbiol Biotechnol       Date:  2022-01-13       Impact factor: 4.813

Review 7.  Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development.

Authors:  Cinzia Colombo; Olimpia Pitirollo; Luigi Lay
Journal:  Molecules       Date:  2018-07-13       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.